Highly efficient therapeutic gene editing of human hematopoietic stem cells
暂无分享,去创建一个
Chunyan Ren | Luca Pinello | Luca Biasco | Kendell Clement | David A. Williams | Mitchel A. Cole | Kevin Luk | Scot A Wolfe | Daniel E Bauer | Alessandra Biffi | Benjamin P. Roscoe | David M Dorfman | Shengdar Q Tsai | Yuxuan Wu | David A Williams | Christian Brendel | S. Tsai | J. Manis | L. Biasco | S. Wolfe | D. E. Bauer | D. Dorfman | C. Brugnara | C. Ren | A. Biffi | Kendell Clement | Mitchel A Cole | Qiuming Yao | Yuxuan Wu | Jing Zeng | Carlo Brugnara | Jing Zeng | Benjamin P Roscoe | Pengpeng Liu | Qiuming Yao | Cicera R Lazzarotto | Cristina Baricordi | Anne H Shen | Erica B Esrick | John P Manis | C. Baricordi | Anne H. Shen | C. Brendel | Pengpeng Liu | C. Lazzarotto | Kevin Luk | David A. Williams | Luca Pinello | Alessandra Biffi
[1] R. Hardison,et al. A genome-editing strategy to treat β-hemoglobinopathies that recapitulates a mutation associated with a benign genetic condition , 2016, Nature Medicine.
[2] Dana Carroll,et al. Selection-free genome editing of the sickle mutation in human adult hematopoietic stem/progenitor cells , 2016, Science Translational Medicine.
[3] Matthew C. Canver,et al. BCL11A enhancer dissection by Cas9-mediated in situ saturating mutagenesis , 2015, Nature.
[4] A. Eddaoudi,et al. Flow Cytometric Detection of G0 in Live Cells by Hoechst 33342 and Pyronin Y Staining. , 2018, Methods in molecular biology.
[5] P. Gregory,et al. Homology-driven genome editing in hematopoietic stem and progenitor cells using zinc finger nuclease mRNA and AAV6 donors , 2015, Nature Biotechnology.
[6] Brian E. McIntosh,et al. Nonirradiated NOD,B6.SCID Il2rγ−/−KitW41/W41 (NBSGW) Mice Support Multilineage Engraftment of Human Hematopoietic Cells , 2015, Stem cell reports.
[7] S. Rodríguez-Perales,et al. Therapeutic gene editing in CD34+ hematopoietic progenitors from Fanconi anemia patients , 2017, EMBO molecular medicine.
[8] Linda Z. Shi,et al. Microhomology-mediated End Joining and Homologous Recombination share the initial end resection step to repair DNA double-strand breaks in mammalian cells , 2013, Proceedings of the National Academy of Sciences.
[9] Jie Li,et al. Global transcriptome analyses of human and murine terminal erythroid differentiation. , 2014, Blood.
[10] Martha L. Bulyk,et al. Direct Promoter Repression by BCL11A Controls the Fetal to Adult Hemoglobin Switch , 2018, Cell.
[11] Shih-Feng Tsai,et al. Cloning of cDNA for the major DNA-binding protein of the erythroid lineage through expression in mammalian cells , 1989, Nature.
[12] R. Laskey,et al. Comparative mutagenesis of nuclear localization signals reveals the importance of neutral and acidic amino acids , 1996, Current Biology.
[13] M. Warr,et al. Hematopoietic stem cell quiescence promotes error-prone DNA repair and mutagenesis. , 2010, Cell stem cell.
[14] Israel Steinfeld,et al. Chemically modified guide RNAs enhance CRISPR-Cas genome editing in human primary cells , 2015, Nature Biotechnology.
[15] Jussi Taipale,et al. CRISPR–Cas9 genome editing induces a p53-mediated DNA damage response , 2018, Nature Medicine.
[16] David A. Williams,et al. Successful hematopoietic stem cell mobilization and apheresis collection using plerixafor alone in sickle cell patients. , 2018, Blood advances.
[17] Matthew C. Canver,et al. Analyzing CRISPR genome-editing experiments with CRISPResso , 2016, Nature Biotechnology.
[18] Matthew C. Canver,et al. CRISPResso: sequencing analysis toolbox for CRISPR genome editing , 2015, bioRxiv.
[19] M. Trivella,et al. Blood transfusion for preventing primary and secondary stroke in people with sickle cell disease. , 2017, The Cochrane database of systematic reviews.
[20] Gang Bao,et al. A high-fidelity Cas9 mutant delivered as a ribonucleoprotein complex enables efficient gene editing in human haematopoietic stem and progenitor cells , 2018, Nature Medicine.
[21] Sangsu Bae,et al. Microhomology-based choice of Cas9 nuclease target sites , 2014, Nature Methods.
[22] J. Joung,et al. CIRCLE-seq: a highly sensitive in vitro screen for genome-wide CRISPR-Cas9 nuclease off-targets , 2017, Nature Methods.
[23] A. Miccio,et al. Plerixafor enables safe, rapid, efficient mobilization of hematopoietic stem cells in sickle cell disease patients after exchange transfusion , 2018, Haematologica.
[24] A. Bradley,et al. Repair of double-strand breaks induced by CRISPR–Cas9 leads to large deletions and complex rearrangements , 2018, Nature Biotechnology.
[25] Matthew C. Canver,et al. miRNA-embedded shRNAs for Lineage-specific BCL11A Knockdown and Hemoglobin F Induction. , 2015, Molecular therapy : the journal of the American Society of Gene Therapy.
[26] Steven Lin,et al. Enhanced homology-directed human genome engineering by controlled timing of CRISPR/Cas9 delivery , 2014, eLife.
[27] G. Lettre,et al. Fetal haemoglobin in sickle-cell disease: from genetic epidemiology to new therapeutic strategies , 2016, The Lancet.
[28] J. D. Macklis,et al. Strict in vivo specificity of the Bcl11a erythroid enhancer. , 2016, Blood.
[29] M. van der Burg,et al. Targeted Genome Editing in Human Repopulating Hematopoietic Stem Cells , 2014, Nature.
[30] D. K. Wood,et al. Deoxygenation Reduces Sickle Cell Blood Flow at Arterial Oxygen Tension. , 2016, Biophysical journal.
[31] Daesik Kim,et al. Highly efficient RNA-guided genome editing in human cells via delivery of purified Cas9 ribonucleoproteins , 2014, Genome research.
[32] C. Beam,et al. Metabolic and immune effects of immunotherapy with proinsulin peptide in human new-onset type 1 diabetes , 2017, Science Translational Medicine.
[33] J. Aster,et al. Validation and Implementation of a Custom Next-Generation Sequencing Clinical Assay for Hematologic Malignancies. , 2016, The Journal of molecular diagnostics : JMD.
[34] Martin J Aryee,et al. Corrigendum: CIRCLE-seq: a highly sensitive in vitro screen for genome-wide CRISPR–Cas9 nuclease off-targets , 2018, Nature Methods.
[35] Margaret A Goodell,et al. Highly Efficient Genome Editing of Murine and Human Hematopoietic Progenitor Cells by CRISPR/Cas9. , 2016, Cell reports.
[36] Laura J. Norton,et al. Natural regulatory mutations elevate the fetal globin gene via disruption of BCL11A or ZBTB7A binding , 2018, Nature Genetics.
[37] L. Symington,et al. Microhomology-Mediated End Joining: A Back-up Survival Mechanism or Dedicated Pathway? , 2015, Trends in biochemical sciences.
[38] Vanessa Taupin,et al. Human hematopoietic stem/progenitor cells modified by zinc-finger nucleases targeted to CCR5 control HIV-1 in vivo , 2010, Nature Biotechnology.
[39] Matthew C. Canver,et al. An Erythroid Enhancer of BCL11A Subject to Genetic Variation Determines Fetal Hemoglobin Level , 2013, Science.
[40] Lei Zhang,et al. Correction of the sickle cell disease mutation in human hematopoietic stem/progenitor cells. , 2015, Blood.
[41] Gregory McAllister,et al. p53 inhibits CRISPR–Cas9 engineering in human pluripotent stem cells , 2018, Nature Medicine.
[42] Luca Pinello,et al. Editing aberrant splice sites efficiently restores β-globin expression in β-thalassemia. , 2019, Blood.
[43] Ke Zhang,et al. Mitochondrial fusion but not fission regulates larval growth and synaptic development through steroid hormone production , 2014, eLife.
[44] Yuri R. Bendaña,et al. Functional footprinting of regulatory DNA , 2015, Nature Methods.
[45] X. Yang,et al. Long-Term Engraftment and Fetal Globin Induction upon BCL11A Gene Editing in Bone-Marrow-Derived CD34+ Hematopoietic Stem and Progenitor Cells , 2017, Molecular therapy. Methods & clinical development.
[46] Sruthi Mantri,et al. CRISPR/Cas9 β-globin gene targeting in human haematopoietic stem cells , 2016, Nature.
[47] Pachai Natarajan,et al. CRISPR-Cas9 gene repair of hematopoietic stem cells from patients with X-linked chronic granulomatous disease , 2017, Science Translational Medicine.
[48] M. Sadelain,et al. Safety and efficacy of plerixafor dose escalation for the mobilization of CD34+ hematopoietic progenitor cells in patients with sickle cell disease: interim results , 2018, Haematologica.